HomeOur expertisePostersPAGE 2024, Rome, ItalyOptimizing first-in-human dose for HPN536, a T-Cell Engager Targeting Mesothelin: comparison of MABEL PK-driven approach and mechanistic translational PK/RO/PA modeling
We use cookies (and other similar technologies) to collect data to improve your experience on our site.
By using our website, you agree to data collection as described in our website’s data collection policy.
